dctp Search Results


cy3 dctp  (Cytiva Europe)
99
Cytiva Europe cy3 dctp
Cy3 Dctp, supplied by Cytiva Europe, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/pm35523820-343-29-30?v=Cytiva+Europe
Average 99 stars, based on 1 article reviews
cy3 dctp - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
biotin 14 dctp  (Jena Bioscience)
94
Jena Bioscience biotin 14 dctp
Biotin 14 Dctp, supplied by Jena Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/bio_rxiv__64898__2026__04__08__717219-243-21-22?v=Jena+Bioscience
Average 94 stars, based on 1 article reviews
biotin 14 dctp - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
dctp  (tiangen biotech co)
99
tiangen biotech co dctp
Dctp, supplied by tiangen biotech co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/pmc03362544-83-29-18?v=tiangen+biotech+co
Average 99 stars, based on 1 article reviews
dctp - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
cyanine 3 cy3 dctp  (Danaher Inc)
96
Danaher Inc cyanine 3 cy3 dctp
Cyanine 3 Cy3 Dctp, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/10__1128_slash_ec__3__6__1639___1652__2004-164-98-109?v=Danaher+Inc
Average 96 stars, based on 1 article reviews
cyanine 3 cy3 dctp - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
α 32 p deoxycytidine triphosphate  (Revvity)
91
Revvity α 32 p deoxycytidine triphosphate
α 32 P Deoxycytidine Triphosphate, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/pmc02435631-126-11-20?v=Revvity
Average 91 stars, based on 1 article reviews
α 32 p deoxycytidine triphosphate - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier
α 32p dctp  (Revvity)
91
Revvity α 32p dctp
α 32p Dctp, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/10__1074_slash_jbc__m115__653287-99-1-7?v=Revvity
Average 91 stars, based on 1 article reviews
α 32p dctp - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier
easytide α 32p dctp  (Revvity)
91
Revvity easytide α 32p dctp
Easytide α 32p Dctp, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/pmc03300023__supp_gkr976_nar___02438___d___2011___File009-45-6-11?v=Revvity
Average 91 stars, based on 1 article reviews
easytide α 32p dctp - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier
dctpp1  (Proteintech)
93
Proteintech dctpp1
Predicting therapy response with NMRS and validation of the core genes. (A) Estimated IC50 values of Tamoxifen and Palbociclib in high- versus low NMRS groups. (B) Estimated IC50 values of Olaparib and Gefitinib in high- versus low NMRS groups. (C, D) The correlation and differential analysis of drug sensitivity for potential drugs screened from the CTRP and PRISM datasets. (E) Validation of the expression of TAGLN2, PCMT1, PTMA, TUBA3D, and <t>DCTPP1</t> in a normal breast cell line (MCF-10A) and three BC cell lines (MDA-MB-231, MCF7, and SK-BR3) by qRT-PCR. (F) Immunohistochemical images showing the protein expression of the five genes in the HPA database. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns p > 0.05. BC breast cancer, HPA Human Protein Atlas.
Dctpp1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/pmc12847018-166-7-8?v=Proteintech
Average 93 stars, based on 1 article reviews
dctpp1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
megaprime dna labeling kit  (Danaher Inc)
95
Danaher Inc megaprime dna labeling kit
Predicting therapy response with NMRS and validation of the core genes. (A) Estimated IC50 values of Tamoxifen and Palbociclib in high- versus low NMRS groups. (B) Estimated IC50 values of Olaparib and Gefitinib in high- versus low NMRS groups. (C, D) The correlation and differential analysis of drug sensitivity for potential drugs screened from the CTRP and PRISM datasets. (E) Validation of the expression of TAGLN2, PCMT1, PTMA, TUBA3D, and <t>DCTPP1</t> in a normal breast cell line (MCF-10A) and three BC cell lines (MDA-MB-231, MCF7, and SK-BR3) by qRT-PCR. (F) Immunohistochemical images showing the protein expression of the five genes in the HPA database. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns p > 0.05. BC breast cancer, HPA Human Protein Atlas.
Megaprime Dna Labeling Kit, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/10__1158_slash_0008___5472__can___04___4041-100-13-17?v=Danaher+Inc
Average 95 stars, based on 1 article reviews
megaprime dna labeling kit - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
dctp α 32 p  (Revvity)
90
Revvity dctp α 32 p
Predicting therapy response with NMRS and validation of the core genes. (A) Estimated IC50 values of Tamoxifen and Palbociclib in high- versus low NMRS groups. (B) Estimated IC50 values of Olaparib and Gefitinib in high- versus low NMRS groups. (C, D) The correlation and differential analysis of drug sensitivity for potential drugs screened from the CTRP and PRISM datasets. (E) Validation of the expression of TAGLN2, PCMT1, PTMA, TUBA3D, and <t>DCTPP1</t> in a normal breast cell line (MCF-10A) and three BC cell lines (MDA-MB-231, MCF7, and SK-BR3) by qRT-PCR. (F) Immunohistochemical images showing the protein expression of the five genes in the HPA database. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns p > 0.05. BC breast cancer, HPA Human Protein Atlas.
Dctp α 32 P, supplied by Revvity, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/pmc04453529-176-9-17?v=Revvity
Average 90 stars, based on 1 article reviews
dctp α 32 p - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cy5  (Danaher Inc)
96
Danaher Inc cy5
Predicting therapy response with NMRS and validation of the core genes. (A) Estimated IC50 values of Tamoxifen and Palbociclib in high- versus low NMRS groups. (B) Estimated IC50 values of Olaparib and Gefitinib in high- versus low NMRS groups. (C, D) The correlation and differential analysis of drug sensitivity for potential drugs screened from the CTRP and PRISM datasets. (E) Validation of the expression of TAGLN2, PCMT1, PTMA, TUBA3D, and <t>DCTPP1</t> in a normal breast cell line (MCF-10A) and three BC cell lines (MDA-MB-231, MCF7, and SK-BR3) by qRT-PCR. (F) Immunohistochemical images showing the protein expression of the five genes in the HPA database. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns p > 0.05. BC breast cancer, HPA Human Protein Atlas.
Cy5, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/10__1677_slash_erc___09___0310-59-33-35?v=Danaher+Inc
Average 96 stars, based on 1 article reviews
cy5 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
phi29 polymerase  (New England Biolabs)
95
New England Biolabs phi29 polymerase
Predicting therapy response with NMRS and validation of the core genes. (A) Estimated IC50 values of Tamoxifen and Palbociclib in high- versus low NMRS groups. (B) Estimated IC50 values of Olaparib and Gefitinib in high- versus low NMRS groups. (C, D) The correlation and differential analysis of drug sensitivity for potential drugs screened from the CTRP and PRISM datasets. (E) Validation of the expression of TAGLN2, PCMT1, PTMA, TUBA3D, and <t>DCTPP1</t> in a normal breast cell line (MCF-10A) and three BC cell lines (MDA-MB-231, MCF7, and SK-BR3) by qRT-PCR. (F) Immunohistochemical images showing the protein expression of the five genes in the HPA database. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns p > 0.05. BC breast cancer, HPA Human Protein Atlas.
Phi29 Polymerase, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dctp/us10246493-264-59-58?v=New+England+Biolabs
Average 95 stars, based on 1 article reviews
phi29 polymerase - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

Image Search Results


Predicting therapy response with NMRS and validation of the core genes. (A) Estimated IC50 values of Tamoxifen and Palbociclib in high- versus low NMRS groups. (B) Estimated IC50 values of Olaparib and Gefitinib in high- versus low NMRS groups. (C, D) The correlation and differential analysis of drug sensitivity for potential drugs screened from the CTRP and PRISM datasets. (E) Validation of the expression of TAGLN2, PCMT1, PTMA, TUBA3D, and DCTPP1 in a normal breast cell line (MCF-10A) and three BC cell lines (MDA-MB-231, MCF7, and SK-BR3) by qRT-PCR. (F) Immunohistochemical images showing the protein expression of the five genes in the HPA database. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns p > 0.05. BC breast cancer, HPA Human Protein Atlas.

Journal: Frontiers in Oncology

Article Title: Spatial transcriptome and single-cell sequencing reveal the role of nucleotide metabolism in breast cancer progression and tumor microenvironment

doi: 10.3389/fonc.2025.1703778

Figure Lengend Snippet: Predicting therapy response with NMRS and validation of the core genes. (A) Estimated IC50 values of Tamoxifen and Palbociclib in high- versus low NMRS groups. (B) Estimated IC50 values of Olaparib and Gefitinib in high- versus low NMRS groups. (C, D) The correlation and differential analysis of drug sensitivity for potential drugs screened from the CTRP and PRISM datasets. (E) Validation of the expression of TAGLN2, PCMT1, PTMA, TUBA3D, and DCTPP1 in a normal breast cell line (MCF-10A) and three BC cell lines (MDA-MB-231, MCF7, and SK-BR3) by qRT-PCR. (F) Immunohistochemical images showing the protein expression of the five genes in the HPA database. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns p > 0.05. BC breast cancer, HPA Human Protein Atlas.

Article Snippet: The antibodies used in this study include: DCTPP1 (Proteintech, # 16684-1-AP, 1:1000), β-Actin (Proteintech, #66009-1-Ig, 1:5000) and anti-Rabbit secondary antibody (Proteintech, Cat: #SA00001-2, 1:5000).

Techniques: Biomarker Discovery, Expressing, Quantitative RT-PCR, Immunohistochemical staining

DCTPP1 expression and functional validation in BC (A) DCTPP1 mRNA expression was higher in TCGA-BRCA tumor tissues than in normal tissues ( p < 0.01). (B) Overall survival was worse in TCGA-BRCA patients with high DCTPP1 expression ( p < 0.0001). (C) ROC curve analysis of DCTPP1, highlighting its diagnostic potential. (D) Single-cell analysis showed ( GSE161529 ) that DCTPP1 expression was significantly higher in NUhighepi cells than in others. (E, F) WB and qpcr analysis of the knockdown efficiency of DCTPP1 in MDA-MB-231 (E) and SK-BR-3 (F) cells and showed that the DCTPP1 gene was successfully knocked down in MDA-MB-231 and SK-BR-3 cell lines. (G) CCK-8 showed that the proliferation activity of the cells that knockdown DCTPP1 was dramatically reduced. (H) After DCTPP1 knockdown, the cloning ability of MDA-MB-231 and SK-BR-3 cell lines decreased significantly. (I) Healing test. After DCTPP1 knockdown, the migration ability of MDA-MB-231 and SK-BR-3 cell lines decreased significantly. (J) Transwell assay. After DCTPP1 knockdown, the migration and invasion abilities of MDA-MB-231 and SK-BR-3 cell lines were significantly decreased. **** p < 0.0001, *** p < 0.001, * p < 0.05, ns p > 0.05.

Journal: Frontiers in Oncology

Article Title: Spatial transcriptome and single-cell sequencing reveal the role of nucleotide metabolism in breast cancer progression and tumor microenvironment

doi: 10.3389/fonc.2025.1703778

Figure Lengend Snippet: DCTPP1 expression and functional validation in BC (A) DCTPP1 mRNA expression was higher in TCGA-BRCA tumor tissues than in normal tissues ( p < 0.01). (B) Overall survival was worse in TCGA-BRCA patients with high DCTPP1 expression ( p < 0.0001). (C) ROC curve analysis of DCTPP1, highlighting its diagnostic potential. (D) Single-cell analysis showed ( GSE161529 ) that DCTPP1 expression was significantly higher in NUhighepi cells than in others. (E, F) WB and qpcr analysis of the knockdown efficiency of DCTPP1 in MDA-MB-231 (E) and SK-BR-3 (F) cells and showed that the DCTPP1 gene was successfully knocked down in MDA-MB-231 and SK-BR-3 cell lines. (G) CCK-8 showed that the proliferation activity of the cells that knockdown DCTPP1 was dramatically reduced. (H) After DCTPP1 knockdown, the cloning ability of MDA-MB-231 and SK-BR-3 cell lines decreased significantly. (I) Healing test. After DCTPP1 knockdown, the migration ability of MDA-MB-231 and SK-BR-3 cell lines decreased significantly. (J) Transwell assay. After DCTPP1 knockdown, the migration and invasion abilities of MDA-MB-231 and SK-BR-3 cell lines were significantly decreased. **** p < 0.0001, *** p < 0.001, * p < 0.05, ns p > 0.05.

Article Snippet: The antibodies used in this study include: DCTPP1 (Proteintech, # 16684-1-AP, 1:1000), β-Actin (Proteintech, #66009-1-Ig, 1:5000) and anti-Rabbit secondary antibody (Proteintech, Cat: #SA00001-2, 1:5000).

Techniques: Expressing, Functional Assay, Biomarker Discovery, Diagnostic Assay, Single-cell Analysis, Knockdown, CCK-8 Assay, Activity Assay, Cloning, Migration, Transwell Assay